CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $1.31B, above the global median of $1.15B
- FinancialsAltman Z-Score -0.6: distress zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.31BUSDvs all stocks (USD)
Revenue (TTM)
787.08MUSDvs all stocks (USD)
Profit Margin
-15.93%vs Medical Devices peers
Beta
0.8520xvs all stocks
52-Week Change
-17.17%vs all stocks
Market Capitalization
1.31BUSDvs all stocks (USD)
Enterprise Value
1.88BUSDvs all stocks (USD)
Forward P/E
16.01xvs Medical Devices peers
Price to Sales (TTM)
1.81xvs Medical Devices peers
Enterprise to Revenue
2.38xvs Medical Devices peers
Enterprise to EBITDA
66.08xvs Medical Devices peers
Gross Margin
71.04%vs Medical Devices peers
Profit Margin
-15.93%vs Medical Devices peers
Operating Margin
-11.48%vs Medical Devices peers
Return on Assets (TTM)
-3.81%vs Medical Devices peers
Revenue (TTM)
787.08MUSDvs all stocks (USD)
Revenue per Share (TTM)
5.18USDUpdated Jul 18, 2026Quarterly Revenue Growth
13.60%vs Medical Devices peers
Gross Profit (TTM)
552.37MUSDvs all stocks (USD)
EBITDA (TTM)
26.20MUSDvs all stocks (USD)
Net Income (TTM)
-125.36MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
13.55%vs Medical Devices peers
Operating Cash Flow (TTM)
51.56MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
54.57MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
764.15MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
232.27MUSDFY2025 · Dec 31, 2025Gross Profit
531.89MUSDFY2025 · Dec 31, 2025Operating Income
-57.97MUSDvs all stocks (USD)
Pre-tax Income
-143.40MUSDFY2025 · Dec 31, 2025Income Tax Expense
-45.00KUSDFY2025 · Dec 31, 2025Net Income
-143.36MUSDFY2025 · Dec 31, 2025EBIT
-97.48MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
26.20MUSDFY2025 · Dec 31, 2025Research & Development
76.27MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
498.53MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
45.92MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.9600USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.9600USDFY2025 · Dec 31, 2025Basic Shares Outstanding
150.06MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
150.06MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-143.36MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-1.80MUSDFY2025 · Dec 31, 2025Free Cash Flow
-44.26MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
160.81MUSDFY2025 · Dec 31, 2025Income Tax Paid
389.00KUSDFY2025 · Dec 31, 2025Interest Paid
23.82MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-143.36MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
82.56MUSDFY2025 · Dec 31, 2025Stock-based Compensation
73.72MUSDFY2025 · Dec 31, 2025Other Non-cash Items
30.90MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-21.88MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-11.16MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-12.59MUSDFY2025 · Dec 31, 2025Capital Expenditures
-42.45MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-7.19MUSDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-3.00MUSDFY2025 · Dec 31, 2025Other Investing Activity
-770.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-46.23MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
407.00MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-332.19MUSDFY2025 · Dec 31, 2025Other Financing Charges
-45.31MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
29.50MUSDFY2025 · Dec 31, 2025Shares Outstanding
151.99MSharesUpdated Jul 18, 2026Float Shares
121.52MSharesUpdated Jul 18, 2026Shares Short
14.62MSharesUpdated Jul 18, 2026Short Ratio
4.50daysvs all stocks
Short % of Shares Outstanding
10.98%vs all stocks
% Held by Insiders
20.47%vs all stocks
% Held by Institutions
77.55%vs all stocks
Total Cash (MRQ)
139.91MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.9100USDUpdated Jul 18, 2026Total Debt (MRQ)
603.06MUSDvs all stocks (USD)
Current Ratio (MRQ)
1.90xvs Medical Devices peers
Book Value per Share (MRQ)
-0.0350USDUpdated Jul 18, 2026Total Assets
791.21MUSDvs all stocks (USD)
Total Current Assets
450.88MUSDFY2025 · Dec 31, 2025Total Liabilities
778.78MUSDFY2025 · Dec 31, 2025Total Non-current Assets
340.33MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
559.61MUSDFY2025 · Dec 31, 2025Total Current Liabilities
219.18MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
160.81MUSDFY2025 · Dec 31, 2025Accounts Receivable
97.30MUSDFY2025 · Dec 31, 2025Inventory
169.44MUSDFY2025 · Dec 31, 2025Accounts Payable
40.89MUSDFY2025 · Dec 31, 2025Short-term Debt
70.82MUSDFY2025 · Dec 31, 2025Deferred Revenue
10.44MUSDFY2025 · Dec 31, 2025Other Current Liabilities
5.94MUSDFY2025 · Dec 31, 2025Long-term Debt
525.27MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
3.12MUSDFY2025 · Dec 31, 2025Common Stock (Book)
14.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.42BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
12.43MUSDvs all stocks (USD)
Treasury Stock
25.10MUSDFY2025 · Dec 31, 202552-Week Low
6.82USDUpdated Jul 18, 202652-Week High
23.29USDUpdated Jul 18, 202652-Week Change
-17.17%vs all stocks
Beta
0.8520xvs all stocks
50-Day MA
8.41USDUpdated Jul 18, 2026200-Day MA
13.87USDUpdated Jul 18, 2026Avg 10-Day Volume
2.14MSharesUpdated Jul 18, 2026Avg 30-Day Volume
2.94MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-0.8300USDUpdated Jul 18, 2026Other Income / Expense
-39.52MUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Within or Near the Altman Distress Zone
Debt is a large share of its assets, and large against its cash flow.
Reads
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
Elevated Leverage on Three Denominators
Debt sits high against its equity, its assets, and its cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.71Profit Margin: -0.16
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 1.90Altman Z-Score: -0.60
Financial Health
Altman Z-Score -0.6: distress zoneCritical
Altman Z-Score: -0.60
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $1.31B, above the global median of $1.15BNotable
Market cap (USD): 1,312,591,718Global Median: 1,146,734,693.424
Revenue is $787.08M, above the global median of $520.53MNotable
Revenue (USD): 787,083,008Global Median: 520,528,949.311
Levered free cash flow is $54.57M, above the global median of $16.24MNotable
Levered free cash flow (USD): 54,572,248Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Shandong Weigao Orthopaedic Device Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
SUDEEPPHRM
Tier 1ProductionApproval-Gated PipelineRuleFlow
North China Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Immatics N.V.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Shanghai Opm Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Sinocare Inc.
Tier 1ProductionApproval-Gated PipelineRule
Conmed Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Aurisco Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Xencor Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Beijing Winsunny Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Eternal Asia Supply Chain Co., Ltd.
3 interpretationsElevated Leverage on Three DenominatorsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedWithin or Near the Altman Distress Zone
Hunan Huamin Holdings Co., Ltd.
3 interpretationsElevated Leverage on Three DenominatorsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedWithin or Near the Altman Distress Zone
Baota Industry Co., Ltd.
3 interpretationsElevated Leverage on Three DenominatorsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedWithin or Near the Altman Distress Zone